Serkan Güngör

Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors.

AimTo compare response assessment according to the WHO, RECIST 1.1, EORTC, and PERCIST criteria in patients diagnosed with malignant solid tumors and who had received cytotoxic chemotherapy to establish the strength of agreement between each criterion. Materials and methodsSixty patients with malignant solid tumors were included in this retrospective study. The baseline and the sequential follow-up fluorine-18-fluorodeoxyglucose PET/computed tomography (CT) of each patient were evaluated according to the WHO, RECIST 1.1, EORTC, and PERCIST criteria. PET/CT images were used for both metabolic and anatomic evaluation. The concurrent diagnostic CT and MRI images (performed within 1 week of PET/CT) were also utilized when needed. The results were compared using the &kgr;-statistics. ResultsThe response and progression rates according to the WHO criteria were 37 and 38%, respectively. The same ratios were also found for RECIST 1.1 (&kgr;=1). The response and progression rates according to the EORTC criteria were 47 and 40%, respectively. When PERCIST criteria were used, one patient with progressive disease was upgraded to stable disease (&kgr;=0.976). As we found the same results with WHO and RECIST 1.1 criteria, we used WHO criteria to compare the anatomic and metabolic criteria. When we compared the WHO and EORTC criteria, there was an agreement in 80% of the patients (&kgr;=0.711). With WHO and PERCIST criteria, there was an agreement in 81.6% of the patients (&kgr;=0.736). ConclusionSignificant agreement was detected when the WHO, RECIST 1.1, EORTC, and PERCIST criteria were compared both within as well as between each other.

FDG PET/CT in Peritoneal Metastasis From Prostate Cancer.

Prostate cancer is one of the leading causes of cancer death in men. The prognosis in prostate cancer is greatly worsened by the presence of metastases, which are most commonly found in bone, lung, liver, and brain. The peritoneum is an extremely uncommon metastatic site for prostate cancer, even in autopsy series. We present a case of FDG PET/CT demonstration of peritoneal metastasis from prostate cancer.

Clinical Impact of Preoperative Sentinel Lymph Node Imaging With SPECT/CT in the Management of Interscapular Malignant Melanoma.

A 31-year-old male patient with a biopsy-proven cutaneous malignant melanoma located in the interscapular area was referred to lymphoscintigraphy for preoperative sentinel lymph node mapping. Anterior and posterior planar images showed 3 hot spots suggesting left axillary sentinel nodes. Herein, we reported the contribution of preoperative SPECT/CT-guided sentinel lymph node excision on accurate staging, management, prognostic evaluation, and determination of the proper surgical positioning preoperatively.

Graves Hastalığı Tedavisinde Sabit 10 mCi ve 15 mCi İyot-131 Dozlarının Karşılaştırılması: 11 Yıllık Tecrübe

Amac: Sabit doz Iyot-131 (RAI) tedavisi, karmasik hesaplamalara ihtiyac duymayan basit ancak etkin bir secenektir. Bu calismada, Graves hastaliginda sabit 10 ve 15 mCi ile RAI tedavisi sonuclari karsilastirildi. Hastalar ve Yontem: 1997-2008 tarihleri arasinda sabit 10 mCi (n:48) ve sabit 15 mCi (n:9) RAI tedavisi almis ve en az 2 yil takip edilmis 55 hastanin takip dosyalari incelenerek basarili (otiroidi, hipotiroidi) ve basarisiz (persiste hipertiroidi) tedavi oranlari ile sonuclara etkili olabilecek parametreler analiz edildi. Bulgular: 10 mCi alan grupta tedavi basari orani %87 (otiroidi %9.1, hipotiroidi %78.2) olarak bulunurken, 15 mCi alan grupta bu deger %100 (hipotiroidi) olarak bulundu. Her iki grup arasinda, kullanilan ortalama propylthiouracil dozu disinda (10 mCi: 190 mg, 15 mCi: 350 mg, p<0.05) anlamli fark izlenmedi. Sonuc: Sabit 10 ve 15 mCi RAI doz uygulamalarinin her ikisi de Graves hastaliginin tedavisinde basarili sonuc vermistir. Sabit 10 mCi verilen hastalarda dusuk oranda da olsa persistan hipertiroidizm izlenebilmektedir Anahtar Kelimeler: Graves hastaligi, Tedavi, Sabit doz, Iyot-131